

It is illegal to post this copyrighted PDF on any website.

Correction

In the article “Oral Ketamine for Depression: A Systematic Review” by Joshua D. Rosenblat, MD; Andre F. Carvalho, MD, PhD; Madeline Li, MD, PhD; Yena Lee, BSc; Mehala Subramanieapillai, MSc; and Roger S. McIntyre, MD, published in the May/June 2019 issue (*J Clin Psychiatry* 2019;80[3]:18r12475), and the letter “Drs Rosenblat and McIntyre Reply” by Joshua D. Rosenblat, MD, and Roger S. McIntyre, MD, published in the January/February 2020 issue (*J Clin Psychiatry* 2020;81[1]:19lr13146a), conflict of interest information for Drs Rosenblat and McIntyre has been corrected to show that Dr McIntyre is the director of and Dr Rosenblat is a staff psychiatrist at a clinic that administers intravenous ketamine, and Dr McIntyre has been on advisory boards and/or received honoraria for educational activities and/or research grants from Takeda, Neurocrine, Allergan, and Sunovion.

You are prohibited from making this PDF publicly available.